{"preliminary_commentary":{"by_channel":{"x_thread":4,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"Oligo-PRESTO","nct_id":"NCT04115007","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=oligo-presto-nct04115007. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Oligo-PRESTO","arms":[{"description":"Standard of care + Stereotactic Body Radiotherapy to oligometastases","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Standard of care","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2031-02-28","type":"ESTIMATED"},"conditions":["Oligometastatic Hormone Sensitive Prostate Cancer"],"enrollment":{"count":550,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Stereotactic Body Radiotherapy (SBRT) + Standard of care","otherNames":[],"type":"RADIATION"},{"name":"Standard of care","otherNames":[],"type":"DRUG"}],"last_update":"2025-06-26","lead_sponsor":"UNICANCER","official_title":"Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06-23","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Castration-resistant prostate cancer free survival","timeFrame":"From randomization to castration resistance or death from any cause, up to 1 year"}],"references":[{"citation":"Petrelli F, Ghidini A, Ghidini M, Bukovec R, Trevisan F, Turati L, Indini A, Seghezzi S, Lonati V, Moleri G, Tomasello G, Zaniboni A. Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res. 2021 May 27;10:423. doi: 10.12688/f1000research.52546.4. eCollection 2021.","pmid":"35602670","type":"DERIVED"}],"start_date":{"date":"2020-06-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients","url":"https://clinicaltrials.gov/study/NCT04115007"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/oligo-presto-nct04115007"}